NCT06592833View on ClinicalTrials.gov

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions
Major Depressive Disorder
Interventions
DRUG

Psilocybin

Psilocybin, 25mg, given once orally.

DRUG

Pimavanserin

Pimavanserin, 34mg, given once orally

DRUG

Placebo

Matching placebo.

Trial Locations (1)

10025

RECRUITING

Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER